The Exchange has sought clarification from Gland Pharma Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Smallcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE and BSE sought clarification from Gland Pharma after its stock fell following a news article about US President Trump sending letters to 17 global drug makers seeking lower prices. Gland Pharma clarified that it is NOT among the recipients of Trump's communication. The company stated it has no undisclosed or price-sensitive information to share, and the decline in its share price was simply due to broader weakness in the pharma and healthcare sector, not any company-specific event. The company also confirmed that no regulatory or legal proceedings are involved in this matter.
The clarification should reassure investors that there is no direct company-specific risk from Trump's drug pricing initiative, as Gland Pharma is not a target. Short-term sentiment may recover, but the stock remains exposed to general pharma sector volatility driven by US policy headlines.